Instil Bio (TIL) Price Target Decreased by 23.15% to 28.22

9d ago, source: Fintel on MSN

The average one-year price target for Instil Bio (NasdaqCM:TIL) has been revised to 28.22 / share. This is an decrease of ...

Jefferies cuts Instil Bio to hold, cites drug discontinuation

on MSN ago, source:

Jefferies downgraded Instil Bio (TIL) to hold, citing discontinuation of clinical development for the company’s drug candidate ITIL-306.

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

19h ago, source:

The net proceeds is expected to fund the Company through the readout of the ongoing Phase 2 trial (AD02) in patients with Early Alzheimer’s Disease (AD) using XPro™ and through the metastatic ...

Inmune Bio Earns Buy Rating on Positive XPro Developments and Strong Financials

17h ago, source:

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inmune Bio (INMB – Research Report), with a ...

INmune Bio Inc (INMB) Stock: Analyzing the Market Value

3d ago, source: newsheater

In conclusion, INmune Bio Inc (INMB) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note ...

BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq

3d ago, source: TMCnet

BIO-key International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB), announced today ...

INmune Bio rises 2%, on $4.5M direct offering

on MSN ago, source:

Clinical-stage immunology company INmune Bio (NASDAQ:INMB) entered into definitive agreements for the sale and purchase of 571,592 shares above market warrant exercise price. Officers, employees and ...